摘要
背景:糖原合成激酶(GSK-3)抑制剂是治疗乳腺癌、肺癌、胃癌等多种癌症的新型药物。GSK-3的形态学检查未见病理改变。 目的:这篇综述描述了最近使用GSK-3抑制剂的程序,主要用于治疗结肠癌。进一步解释了不同GSK-3抑制剂治疗不同类型癌症的作用机制,并提出了一些可能有助于GSK-3抑制剂治疗包括结肠癌在内的癌症的进一步研究的附加机制。 结果:大多数癌变和癌前病变是由膜结合的花生四烯酸(AA)转化为二十烷酸所刺激的,这种转化促进了癌症的生存能力、增殖和扩散。GSK-3抑制剂可以恢复胃腺癌细胞对肿瘤坏死因子相关凋亡诱导配体(TRAIL)反应的敌意。GSK-3是糖原合成的最后一种酶,是一种丝氨酸/苏氨酸激酶,可磷酸化一系列异质性途径中的蛋白质中100多个不同序列。它是大量细胞过程的一个基本模块,在许多代谢过程和疾病中发挥着基本作用。许多被诊断为结肠癌的患者通过GSK-3抑制剂获得了长期缓解并获得了出色的生存率。 结论:在GSK-3抑制剂的这些机制被广泛应用之前,还需要进一步的评估和临床研究。只有在完成适当的临床研究和形态学检查后,才适合广泛应用。
关键词: GSK-3抑制剂,结肠癌,大肠癌,OMM,癌细胞凋亡,DMSO
Erratum In:
GSK-3 Inhibitors in the Regulation and Control of Colon
Carcinoma
Current Drug Targets
Title:GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Volume: 22 Issue: 13
关键词: GSK-3抑制剂,结肠癌,大肠癌,OMM,癌细胞凋亡,DMSO
摘要:
Background: Glycogen syntheis kinase (GSK-3) inhibitors are novel therapeutic agents for treating various types of cancer, such as breast, lung, and gastric cancer. No pathological changes have been found by the morphological examination of GSK-3.
Objectives: This review describes recent procedures using GSK-3 inhibitors, primarily in treating colon carcinoma. Furthermore, it also explains the mechanism of action of different GSK-3 inhibitors in treating various types of cancers and proposes some additional mechanisms may be useful for further research on GSK-3 inhibitors for cancers, including colon carcinoma.
Results: The majority of the cancerous and pre-cancerous lesions are stimulated by the transformation of membrane-bound arachidonic acid (AA) to eicosanoids, a transformation that promotes for the viability, proliferation, and spread of cancer. GSK-3 inhibitors can reinstate hostility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) responsiveness in gastric adenocarcinoma cells. GSK-3, the final enzyme in glycogen synthesis, is a serine/threonine kinase that phosphorylates varied sequences that are more than a hundred in number, within proteins in an array of heterogeneous pathways. It is an essential module of an exceptionally large number of cellular processes, playing a fundamental role in many metabolic processes and diseases. Many patients diagnosed with colon cancer achieve long-term remission with outstanding survival through the GSK-3 inhibitors.
Conclusion: Prior to the extensive application of these proposed mechanisms of GSK-3 inhibitor, further evaluation and clinical studies are needed. Only after the completion of appropriate clinical studies and morphological examinations, would extensive application be apprpriate.
Export Options
About this article
Cite this article as:
GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma, Current Drug Targets 2021; 22 (13) . https://dx.doi.org/10.2174/1389450122666210204203950
DOI https://dx.doi.org/10.2174/1389450122666210204203950 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Sirtuin3 in Neurological Disorders
Current Drug Research Reviews MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets The Interplay between G-quadruplex and Transcription
Current Medicinal Chemistry The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Pharmacokinetics of Selegiline in a Rabbit Model
Letters in Drug Design & Discovery Neurosteroids and Hepatic Encephalopathy: An Update on Possible Pathophysiologic Mechanisms
Current Molecular Pharmacology Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery The Targets of Curcumin
Current Drug Targets FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals